Congratulations to Dr. Khaled Abdelrahman on receiving funding from the Scottish Rite Charitable Foundation of Canada for his research project, Defining the Role of M1 Muscarinic Acetylcholine Receptor Signaling in Alzheimer’s Disease.
Alzheimer’s disease affects memory, thinking, and everyday functioning. Growing evidence suggests that disruptions in cerebral blood flow occur early in the disease and may contribute to its progression. However, relatively little is known about why the brain’s blood flow becomes disrupted and how this contributes to changes in brain function.
The goal of Dr. Abdelrahman’s research is to better understand how cerebral blood flow is regulated and why this process becomes disrupted in Alzheimer’s disease. His lab is particularly interested in M1 muscarinic acetylcholine receptors, proteins involved in communication between brain cells. However, little is known about how M1 receptors contribute to the regulation of cerebral blood flow or how their function may be altered in Alzheimer’s disease.
In this project, Dr. Abdelrahman’s team will use isolated brain cells and animal models, including genetic deletion strategies, to determine how M1 muscarinic acetylcholine receptors contribute to the regulation of cerebral blood flow and memory in Alzheimer’s disease. The study will also examine whether the role of M1 receptors differs between males and females. This work may provide new insights into the mechanisms underlying Alzheimer’s disease and help identify potential targets for future therapeutic approaches.
“Understanding how the brain’s mechanisms for regulating blood flow are affected in Alzheimer’s disease could reveal new ways to protect brain function,” says Dr. Abdelrahman. “Many current therapies only manage symptoms without addressing the underlying problems, so this approach could target a root cause of brain dysfunction in Alzheimer’s disease.”
Overall, this research has the potential to lead to new strategies for slowing or improving memory loss, enhancing quality of life for people living with Alzheimer’s disease, and reducing the emotional and financial burden on families and healthcare systems.
